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Abstract Transsphenoidal surgery (TS) is the treatment
of choice for many pituitary tumors. Because TS may
cause pituitary insufficiency in some of these patients, early
postoperative assessment of pituitary function is essential
for appropriate endocrine management. The aim of our
study was to evaluate the clinical relevance of the CRH-
stimulation test in assessing postoperative pituitary-adrenal
function. We performed a retrospective analysis of 144
patients treated by TS between January 1990 and
November 2009, in whom a CRH-test and a second stim-
ulation test was performed to assess adrenal function dur-
ing follow-up. Patients with Cushing’s disease were
excluded. Hydrocortisone substitution was started if peak
cortisol levels were \550 nmol/L. The cortisol response
was insufficient in 42(29%) and sufficient in 102 patients at
the postoperative CRH-test. Thirteen of 42(30%) demon-
strated a normal cortisol response during a second cortisol
stimulation test. In 75 of the 102 patients with a sufficient
response to CRH repeat testing revealed an insufficient
cortisol response in 14 patients (14%). All but one had
concomitant pituitary hormone deficits. There were no
cases of adrenal crises during follow-up. Additional pitui-
tary insufficiency was significantly more present (P \
0.001) in the group of patients with an abnormal response
to CRH directly after surgery. In this study a substitution
strategy of hydrocortisone guided by the postoperative
cortisol response to CRH appeared safe and did not result
in any case of adrenal crises. However, the early postop-
erative CRH-test does not reliably predict adrenal function
after TS for pituitary adenomas in all patients and retesting
is mandatory.
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Introduction
Transsphenoidal surgery (TS) is the treatment of choice for
many pituitary tumors. TS may result in (additional) pitu-
itary insufficiency in some of these patients [1–3]. There-
fore, accurate assessment of pituitary function is essential
for appropriate management of postoperative patients after
TS. In this respect, evaluation of the pituitary-adrenal axis
is clinically relevant to assess the need for hydrocortisone
replacement therapy at discharge.
The insulin tolerance test (ITT) is considered to be the
gold standard for the evaluation of secondary adrenal
insufficiency [4, 5]. Because there are contraindications for
ITT in some patients, the corticotrophin releasing hormone
(CRH) test, the metyrapone test or the ACTH stimulation
test can be used as alternative dynamic tests to assess
adrenal function [6–8]. However, there is no international
consensus for postoperative testing after pituitary surgery.
We performed a structured literature search for articles that
(1) evaluated the postoperative strategy for evaluation of
adrenal function and (2) use of the CRH test to evaluate the
pituitary-adrenal axis in postoperative patients after TS for
pituitary adenomas, excluding manuscripts on patients with
Cushing’s disease. However, specific data on this topic are
hardly available.
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Moreover, studies that compared CRH test and other
dynamic test in other situations (i.e. in patients with (sus-
pected) hypothalamic-pituitary insufficiency not specifi-
cally related to surgery) reported contradictory results [8,
9]. Therefore, at our center we developed a strategy for
evaluation of patients after pituitary surgery in 1990 using
the CRH test as the first postoperative test. The aim of the
present study was to assess the clinical relevance of the
CRH stimulation test, as a part of this evaluation strategy,
in assessing pituitary-adrenal function after TS. We per-
formed a retrospective analysis of all patients treated by TS
between January 1990 and November 2009, in whom a
CRH test and a second stimulation test was performed to




We performed a retrospective chart review of all patients,
who had been treated by TS in the Leiden University
Medical Center between January 1990 (when human CRH
(hCRH) became available for routine clinical use) and
November 2009. Patients with available data on a post-
surgical CRH-test, who also had a second (confirmation)
test of adrenal function during follow-up were included.
We excluded patients on high dose glucocorticoids, reop-
eration, postoperative cranial radiotherapy, and patients
treated by TS for Cushing’s disease.
The Medical Ethics Committee of our hospital declared
that no formal ethical approval and written informed consent
is needed for this anonymous retrospective chart review.
Endocrine assessment
According to the postoperative protocol, which has been
implemented in our hospital, the pituitary-adrenal axis is
assessed by CRH test 7–10 days after surgery. The CRH test
is performed after an overnight fast, after withdrawal of
hydrocortisone for 24 h, using 100 lg CRH (Corticoliberine,
Ferring Farmaceuticals Hoofddorp, the Netherlands). Venous
blood samples for measurement of ACTH and cortisol con-
centrations are collected at -15, 0, 15, 30, 45 and 60 min after
infusion. A peak plasma cortisol of C550 nmol/L is consid-
ered to reflect a normal response [10, 11].
In case of insufficient cortisol responses to CRH,
hydrocortisone is prescribed (20 mg/day, divided in three
doses). During follow-up, the treating endocrinologist
decided on re-testing of the adrenal function. For the
assessment of the HPA axis during follow-up either basal
serum cortisol levels or a stimulation test was used. The
ITT was performed after an overnight fast by intravenous
administration of insulin (0.10 U/kg, Actrapid, Novo Nor-
disk Farma, Bagsvaerd, Denmark) to induce adequate
hypoglycemia, defined as nadir glucose levels\2.2 mmol/L.
Blood was collected for measurement of cortisol, ACTH and
GH at -15, 0, 15, 30, 45, 60, 90 and 120 min after iv
administration of insulin. Peak values of GH [9 mU/L
(corresponding with 3 lg/L) and cortisol of C550 nmol/L
were considered to reflect normal pituitary function of GH
and ACTH secretion [4, 12–15].
For the ACTH test 1 lg Synacthen (Novartis Pharma,
Arnhem, The Netherlands) was administered i.v. and corti-
sol levels were measured at -15, 0 and 30 min after infu-
sion. A peak cortisol value of C550 nmol/L was considered
to reflect normal adrenal reserve [16–18]. In addition, a basal
serum cortisol concentration of [550 nmol/L was consid-
ered to reflect normal adrenal function [9].
In some patients a metyrapone test was used as a second
test to assess pituitary adrenal function. Metyrapone
(30 mg/kg, Metopiron, Novartis Pharma B.V., Arnhem, the
Netherlands) was administered orally at midnight. The next
morning postabsorptive blood samples were obtained for
measurement of 11-deoxycortisol, cortisol and ACTH
levels. A cut-off value for 11-deoxycortisol of 200 nmol/L
was used to define normal adrenal function [6, 19, 20].
Assays
Between 1986 and 1994, a fluorescence energy-transfer
immunoassay Syva-Advance (Syva Company, Palo Alto,
CA) was used, with an interassay variation coefficient of
3.6–6.1% and a detection limit of 50 nmol/L. From 1994,
cortisol was measured by fluorescencepolarization assay on
a TDx (Abbott Laboratories, Abbott Park, IL). The inter-
assay variation coefficient is 5–6% above 500 nmol/L and
amounts to 12% under 200 nmol/L. The detection limit is
20 nmol/L. The methods correlated well with each other,
and therefore no correction factors were introduced for
follow-up of patients. ACTH was determined by immu-
nolimunimetric assay using an Immulite 2500 (Siemens
Healthcare Diagnostics, Deerfield, IL, USA). The maximal
inter-assay coefficient of variation (CV) was between 5.0
and 10.0%. During the insulin tolerance test glucose levels
were measured using a Modular P800 (Roche Diagnostics,
Mannheim, Germany).
For the measurement of 11-deoxycortisol a radioim-
munoassay (RIA) of Diasource (previously Biosource
Europe, Nivelles, Belgium) was used. CV was approxi-
mately 11%.
FT4, TSH, LH, FSH and prolactine blood levels were
measured by electrochemoluminescent immunoassay
(ECLIA), using a Modular E170, (Roche Diagnostics,
Mannheim, Germany). The maximal inter-assay CV for
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these hormones was 5.0%. ACTH, GH and IGF-I were
determined by immunolimunimetric assay using an Im-
mulite 2500 (Siemens Healthcare Diagnostics, Deerfield,
IL, USA). The maximal inter-assay CV was between 5.0
and 10.0%. Glucose levels were measured using a Modular
P800 (Roche Diagnostics Mannheim, Germany) (CV is
3%). For measurement of estradiol levels a RIA (Orion
Diagnostica, Espoo, Finland) was used (CV is 6% at
70 pmol/L). The estradiol detection limit was 20 pmol/L.
Testosterone was measured using a RIA (Siemens
Healthcare Diagnostics, Deerfield IL, USA). (CV is 20%
at 1.0 nmol/L and 12% at 14 nmol/L) The detection limit
was 0.2 nmol/L.
Statistical analysis
PSAW for Windows version 17.0 (SPSS Inc. Chicago, IL)
was used to perform data analysis. Data are presented as
mean ± SD unless otherwise mentioned. To evaluate the
difference between peak cortisol of the direct postsurgical
CRH test and the confirmation test during follow-up we
used a paired t-test. A v2-test was used to evaluate the
difference in prevalence of additional pituitary insuffi-
ciency in patients diagnosed with or without adrenal
insufficiency based on the CRH stimulation test. The level
of significance was set at P B 0.05.
Results
Patients
Between January 1990 and November 2009, 291 patients
were treated by TS for non-functioning pituitary adenomas
(NFA, n = 160), GH-producing adenomas (n = 96), pro-
lactinomas (n = 16) or other pituitary tumors (n = 19)
(Fig. 1). A CRH test directly following surgery was not
indicated in 13 patients because of cortisol levels below or
above the reference rages of normal (\100 nmol/L and
[550 nmol/L, respectively). In addition no CRH test was
performed in 69 patients for several reasons: pituitary
insufficiency prior to surgery n = 29, follow-up in outpa-
tient clinic n = 11, peri-operative steroid use n = 5, ITT
directly after surgery n = 7 and loss to follow-up n = 30.
Consequently, a CRH test was performed in 209 postop-
erative patients after TS. In 65 of these 209 patients, there
was no additional adrenal test performed in follow-up
between TS and referral for postoperative radiotherapy
(n = 24), repeat surgery (n = 5), or death of the patient
(n = 10), or due to follow-up in another hospital (n = 17)
and loss to follow-up (n = 9). Therefore, 144 patients were
finally included in this study. Baseline characteristics of
these 144 patients are presented in Table 1.
Patients with a decreased postoperative cortisol
response to CRH (n = 42)
The peak levels of cortisol during the postoperative CRH-
test classified 42 of the 144 patients with pituitary-adrenal
insufficiency (peak cortisol \ 550 nmol/L) (Fig. 1). In 22
of these 42 patients with a median peak cortisol response to
Transsphenoidal surgery               
(n=291)
Excluded:
No CRH test after surgery (n=82)
Loss to follow-up (n=65)
Total number of patients              
(n=144)
CRH test:                                    
Peak cortisol < 550 nmol/l  
(n=42)
No dynamic test              
(n=20)*
AI    
(n=9)
No AI  
(n=13)
Dynamic test                   
(n=22)
AI    
(n=20)
CRH test:                                    
Peak cortisol > 550 nmol/l  
(n=102)
No dynamic test              
(n=27)**
AI    
(n=13)
No AI  
(n=62)
Dynamic test                    
(n=75)
AI    
(n=1)
No AI  
(n=26)
Fig. 1 Flow-chart of patient selection and follow-up. AI = adrenal
insufficiency. *pre-existent panhypopituitarism before or immediately
after surgery (n = 12), pre-existent isolated severe adrenal insuffi-
ciency before surgery (n = 4) or very low basal serum cortisol
concentrations (mean 10 nmol/L) during follow-up after surgery
(n = 4). **basal serum cortisol levels [ 550 nmol/L (n=12), normal
urine cortisol levels (n=3), short follow-up between repeated surgery or
additional radiotherapy (n = 2), and follow-up \1 year (n = 2) or
unspecified reasons (n = 7), basal serum cortisol\110 nmol/L (n = 1)
Table 1 Baseline characteristics
Baseline characteristics Number of patients
(n = 144)
Gender (M/F) 71/73





Other pituitary tumors 5




Confirmation test (n = 97)
ITT 55
CRH 16
ACTH stimulation test 21
Metyrapone test 5
a Basal serum cortisol was low, however CRH test peak cortisol 0.61
therefore 2 days after CRH test a metyrapone test was performed
438 Pituitary (2012) 15:436–444
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CRH of 480(30–547) nmol/L, a second stimulation test was
performed during follow-up: ITT (n = 8), ACTH stimu-
lation test (n = 8), CRH stimulation test (n = 5) and
metyrapone test (n = 1). These confirmation tests were
performed with a median interval of 27.5 (1–139) months
after the initial postoperative CRH test. Based on this
repeat test, 9 of these 22 (41%) patients had persistent
adrenal insufficiency [median initial cortisol response 356
(30–547); median cortisol response confirmation test 219
(3–514)], who received hydrocortisone replacement and 13
(59%) with a normal response, in whom HC was discon-
tinued. In these 13 patients, the median peak cortisol level
to postoperative CRH stimulation was 480 (340–543)
nmol/L, whereas the median peak cortisol level during the
second test were 672 (570–890) nmol/L (P \ 0.001). The
clinical characteristics of these patients are detailed in
Table 2. Based on the results of the CRH test 4 patients did
not receive HC directly after surgery, or only if necessary.
In two of these patients (Table 3 patient 2 and 8) the
physician defined the HPA axis as normal based on the
peak cortisol of the CRH test (540 and 543 nmol/L
respectively). No clinical events were reported.
In 20 of these 42 patients with a median CRH stimulated
cortisol concentration of 194 (6–510) nmol/L, no addi-
tional stimulation test of adrenal function was performed
during follow-up. Persistent adrenal insufficiency was
considered to be present in these 20 patients because of
pre-existent panhypopituitarism before or immediately
after surgery (n = 12), pre-existent isolated severe adrenal
insufficiency before surgery (n = 4) or very low basal
serum cortisol concentrations (mean 10 nmol/L) during
follow-up after surgery (n = 4). Accordingly, all these
patients received hydrocortisone supplementation directly
after the post surgical CRH test until now.
Patients with a normal postoperative cortisol response
to CRH (n = 102)
The peak levels of cortisol during the postoperative CRH-
test classified 102 of the 144 patients with normal pituitary-
adrenal function (peak cortisol [ 550 nmol/L) (Fig. 1). In
75 of these 102 patients, adrenal function was assessed
during follow-up using a second stimulation test in the
remaining 27 no stimulation test was used because of basal
serum cortisol levels [550 nmol/L (n = 12), normal urine
cortisol levels (n = 3), short follow-up between repeated
surgery or additional radiotherapy (n = 2), and follow-up
\1 year (n = 2) or unspecified reasons (n = 7). One
patient returned within 3 months after surgery with com-
plaints and basal postabsorptive serum cortisol levels of
90 nmol/L and HC was started without additional stimu-
lation test. The ITT was used in 49 of the 75 patients, the
CRH test in 11 patients, the ACTH stimulation test in 11,
and the metyrapone test in four patients. A normal response
to these tests was found in 62 patients. However, 13
patients had an insufficient adrenal response to these tests.
With the inclusion of the patient with very low basal serum
cortisol levels (see above), 14 patients were classified as
adrenal insufficient (Table 3). Thirteen of these 14 patients
had been diagnosed with any other additional pituitary
insufficiencies and eight of these patients (57%) had pan-
hypopituitarism. Six patients already received HC directly
after surgery. None of these 14 patients experienced any
clinical event related to cortisol deficiency.
Prevalence of additional pituitary insufficiency
A total of 73 patients had additional pituitary insufficiency.
The prevalence of additional pituitary insufficiency was
significantly higher in patients diagnosed with an insuffi-
cient CRH stimulation test after surgery compared to
patients with a normal test result (any hypopituitarism
P \ 0.001; GHD P \ 0.001; TSH deficiency P \ 0.001;
LH/FSH deficiency P = 0.001).
Discussion
This study evaluated the postoperative response of cortisol to
CRH stimulation in a large cohort of patients after TS for
pituitary adenomas compared with the adrenal function
assessed during postoperative follow-up. The second adrenal
function test documented a normal cortisol response in 31% of
the patients with a decreased cortisol response to CRH stim-
ulation directly after surgery. Conversely, the second adrenal
stimulation test documented an insufficient cortisol response
in 14% of the patients with a normal cortisol response to direct
postoperative CRH stimulation. Therefore, the postoperative
CRH test does not reliably predict adrenal function after TS
for pituitary adenomas in all patients. Nonetheless, our sub-
stitution strategy of hydrocortisone guided by the postopera-
tive cortisol responses to CRH did not result in any case of
adrenal crises in our patients.
Although CRH stimulation has been incorporated in the
diagnostic procedures of ACTH dependent Cushing’s
syndrome [21–23], reports on the use of CRH stimulation
to assess cortisol dependency after transsphenoidal surgery
for other pituitary adenomas are scarce. We found three
publications that assessed pituitary function using CRH,
but these were not specifically in patients after transsphe-
noidal surgery [8, 9]. Dullaart et al. [9] and Schmidt et al.
[8] compared the CRH test with basal serum cortisol levels
and found no higher diagnostic applicability of the CRH
test to basal morning cortisol levels. In contrast, Maghnie
et al. concluded that the CRH test provided better results
than the short Synacthen test (SST) and low-dose short
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Synacthen test (LDSST), and that CRH may be useful in
patients who have a contraindication for ITT [7].
In the current study, the postoperative CRH stimulation test
classified 42 of the 144 patients with hypocortisolism. How-
ever, 13 of these patients had sufficient adrenal function
during follow-up. There are several explanations for these
discrepant results. They may be related to differences in cut-
off values of the different tests. Regularly accepted cut-off
values (500–550 nmol/L) have been defined for the ITT,
which still remains the gold standard test for the assessment of
the HPA-axis. For the CRH test, some authors have proposed
different cut-off values for peak cortisol responses. For
example, Schmidt et al. [8] reported an optimal peak cortisol
cut off of\377 nmol/L, yielding a 96% specificity, but poor
sensitivity of 76% for the diagnosis of adrenal insufficiency. A
sensitivity of 100% was reached using a peak cortisol levels of
514 nmol/L (with a specificity of 32%), and 100% specificity
with peak cortisol levels of 349 nmol/L (sensitivity 66%).
Dullaart et al. found that a peak cortisol value of 420 nmol/L
reflected 100% specificity, but 100% sensitivity for the CRH
test was only reached using a peak cortisol of 615 nmol/L.
Because in our center the CRH test is used as a screening test
for hypocortisolism after TS to identify those patients that
require hydrocortisone supplementation, we applied a gen-
erally accepted stringent criterion of 550 nmol/L. The data
indicate that this choice for a higher sensitivity of the CRH test
is at the expense of a lower specificity. In other words, using
this strategy a higher proportion of patients will be incorrectly
diagnosed with adrenal insufficiency. Based on the available
literature the use of a cut-off levels of peak cortisol of
514 nmol/L would have resulted in 4/13 patients which would
not have been diagnosed with adrenal insufficiency, but with
the criteria suggested by Dullaart et al. even more patients
would have had discrepant results [8, 9].
Recovery of preoperative adrenal insufficiency follow-
ing TS has been described previously [24, 25]. In a recent
study that compared the ITT response at 3 and 12 months
after TS, recovery of adrenal function was demonstrated
within the first year [26]. In agreement, we found a normal
function of the HPA-axis in eight patients within the first
year after surgery who were initially diagnosed as being
adrenal insufficient, indicating the necessity of an extensive
follow-up in patients after surgery within one year.
In the current study, the postoperative CRH test classified
102 of the 144 patients as having a normal functioning of the
HPA-axis based on the post-operative CRH test. Fourteen
percent of these patients later proved to have hypocortiso-
lism by a second test. These discrepant test results can be
potentially life-threatening because these patients are at risk
for adrenal crises. It is possible that additional pituitary
insufficiencies affected pituitary-adrenal function. Growth
hormone and thyroid hormone deficiency can influence these
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with growth hormone deficiency may also play an important
role because of the influence of GH on the cortisol metab-
olism. Growth hormone stimulates 11-b hydroxysteroid
dehydrogenase (11bHSD-1), leading to increased cortisol-
cortisone interconversion [27]. The use of GH replacement
therapy in GH-deficient patients may therefore unmask
cortisol deficiency [28, 29]. This may also be the case in
some of our patients, because their adrenal insufficiency
became clear after start of rhGH therapy. Despite all the
confounding factors none of our patients had a clinical event.
In conclusion, the CRH-test can be safely used to guide
hydrocortisone substitution after TS. Nonetheless, the cor-
tisol response to this test cannot reliably predict adrenal
function in all patients during longer follow-up after TS. We
therefore recommend to perform a second test of pituitary
adrenal function during longer follow-up, e.g. 3–6 months
after surgery (see Fig. 2). This approach is not required in
patients with an impaired postoperative cortisol response to
CRH, who have multiple pituitary insufficiencies.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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Fig. 2 Proposed algorithm for the postoperative follow-up of adrenal
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